HUMA — Humacyte Income Statement
0.000.00%
Last trade - 00:00
- $475.14m
- $413.55m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 6.19 | 1.49 | 1.26 | 1.56 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 91.9 | 66.1 | 79.2 | 86.1 | 99.4 |
Operating Profit | -85.7 | -64.6 | -77.9 | -84.6 | -99.4 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -85.4 | -66.5 | -26.5 | -12 | -111 |
Net Income After Taxes | -85.4 | -66.5 | -26.5 | -12 | -111 |
Net Income Before Extraordinary Items | |||||
Net Income | -85.4 | -66.5 | -26.5 | -12 | -111 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -85.4 | -66.5 | -26.5 | -12 | -111 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.829 | -0.646 | -0.289 | -0.116 | -1.08 |
Dividends per Share |